EMP16

Empros Pharma has developed a revolutionary drug – EMP16.

The main mechanism of action for EMP16 is to delay normal food digestion and absorption processes towards the end of the small intestine. EMP16 is based on a proprietary advanced drug delivery technology, designed to have features that optimizes its effect throughout the gastrointestinal system.

EMP16 is an oral product with a local effect in the gastrointestinal systems. It is a fixed dose combination of two locally active, safe and established active drugs (orlistat and acarbose). The advanced multiple unit, modified release formulation is designed to maximize the effect of the drugs as well as improving tolerability.

Conventional orlistat

  • Inhibits breakdown of triglyceride and thereby the absorption of free fatty acids
  • The conventional formulation has a rapid release resulting in an early and strong inhibition
  • Altered release of free fatty acids causes increases gastric emptying into the intestines and diarrhea
  • Detrimental effect on tolerability and efficacy 

Conventional acarbose

  • Delays breakdown of carbohydrates and thereby prolongs the absorption of glucose
  • Causes a substantial release of undigested carbohydrates into the intestens
  • Detrimental effect on tolerability and efficacy 

EMP16

Increases efficacy ​
  • Optimizes the breakdown of carbohydrates and fat int the intestines
  • Triggers endogenous satiety response
Decreases side effects 
  • Synergistically slows down gastric emptying
  • Dramatically reduces fecal incontinence
  • Reduces oily stool 

Conventional orlistat

  • Orlistat inibit brakdown of triglycerides and thereby the absorption of free fatty acids (“energy leaks out”)
  • Acarbose delays breakdown of carbohydrates and thereby prolongs the absorption of glucose (lowes insulin)
  • Unquestionable safety
  • Both have an unfavorable efficac/tolerability ration

Conventional acarbose

EMP16

  • Delivery of the drug into targeted areas of the gastrointestinal tract
  • Increases efficacy
  • Maintained safety
  • Enables combination of orlistat and acarbose without tolerability isseus.
Novel and proprietary fixed combination of olistat and acarbose with modified-release formulation effect and tolerability.